Formulary guidance and transparency from P&T to point of care

Trends That Matter for Biosimilars

Posted by Matt Breese on Jun 22, 2017

Find me on:

In our weekly Trends that Matter series, we provide engaging infographics and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is the Supreme Court's recent Sandoz-Amgen decision in favor of biosimilar developers. 

This ruling will give patients earlier access to a wider variety of treatment options. According to Genetic Engineering & Biotechnology News, biosimilar developers will no longer need to wait an additional six months to introduce their treatments to market.

The pharmaceutical industry is no stranger to disruptive market events like this one. Pharma brand teams need to follow these changes in real-time. When drugs are preparing to launch, MMIT springs into action with a proven process for identifying new drugs and the category they will be placed in. MMIT's technology helps solves market access challenges by analyzing coverage and restrictions across thousands of plans for competing products. 

In the graphic below, Sandoz provides a summary of the U.S. Supreme Court ruling:

Trends that Matter for Biosimilars- Crop.png

Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Industry Trends, Market Access